These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8353075)

  • 41. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K; Watanabe H; Kobayashi T; Maegawa M
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract]   [Full Text] [Related]  

  • 43. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
    Bajorin DF; Nichols CR; Schmoll HJ; Kantoff PW; Bokemeyer C; Demetri GD; Einhorn LH; Bosl GJ
    J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
    J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of cisplatin-based chemotherapy in advanced urothelial tract cancer.
    Yagoda A
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):98-104. PubMed ID: 2669142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy of urothelial tract tumors.
    Yagoda A
    Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H; Obata K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
    Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
    Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):589-94. PubMed ID: 17564101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer].
    Okaneya T; Tsuruta T; Niwakawa M; Kawakami M; Kobayashi S; Ogawa A
    Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):680-5. PubMed ID: 7684099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
    Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
    Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL; Jakubowski A; Scher H; Sternberg C; Wong G; Grous J; Yagoda A; Fain K; Moore MA; Clarkson B; Oettgen HF; Alton K; Welte K; Souza L
    N Engl J Med; 1988 Jun; 318(22):1414-22. PubMed ID: 2452983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Granulocyte function of patients on anti-cancer chemotherapy].
    Okada H; Miyazaki J; Kamidono S
    Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):958-63. PubMed ID: 7520515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.